HR Execs on the Move

Principia Biopharma

www.principiabio.com

 
Principia Biopharma is a privately-held biopharmaceutical company focused on the discovery and development of best-in-class small molecule drugs for autoimmune diseases and cancer. The company uses its proprietary technology, licensed from the University of California San Francisco, to enable a new approach to making small molecules that are potent, safe and have antibody-like specificity. Principia raised $40 million in a Series A round of financing from a leading group of healthcare investors, including New Leaf Venture Partners, OrbiMed Advisors, Morgenthaler Ventures, SROne and Mission Bay Capital.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.principiabio.com
  • 400 E Jamie Ct Suite 302
    South San Francisco, CA USA 94080
  • Phone: 650.416.7700

Executives

Name Title Contact Details
Betsy Santos
Head of Human Resources Profile

Similar Companies

Genome Sciences Centre

Genome Sciences Centre is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer.

InterveXion Therapeutics

At InterveXion we develop novel products for the treatment of addiction disorders. Since our founding in 2004, our team has been dedicated to providing therapeutic options for patients suffering from the debilitating effects of addiction. We occupy office and laboratory space in the BioVentures Building on the campus of the University of Arkansas for Medical Sciences (UAMS), from whom we licensed our lead technology.

ThinSpring

ThinSpring is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Revance

Revance Therapeutics is a biotechnology company developing neuromodulators for use in treating aesthetic and underserved therapeutic conditions, including muscle movement disorders and pain. The company`s lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. Revance has developed a proprietary, stabilizing excipient peptide technology designed to create novel, differentiated therapies. The company has a comprehensive pipeline based upon its peptide technology, including injectable and topical formulations of daxibotulinumtoxinA.